Global Sublicensing Plan
CONNECTING THE WORLD WITH PROMISING PRODUCTS
Virpax engaged Destum Partners to seek global partners to sublicense OTC, Device, and Animal Health.
AnQlar™
High-density molecular intranasal spray
IND Enabling Trials Completed
AnQlar™
High-density molecular intranasal spray
IND Enabling Trials Completed
TARGET MARKET
Prophylactic barrier to negatively charged viruses like Covid-19 and influenza
DELIVERY PLATFORM
Intranasal MET-nanoparticle dispersion delivery
POTENTIAL BENEFITS
- An adjuvant to barrier-based personal protective equipment (PPE) to help mitigate the risks of poorly fitting equipment and over-used PPE with partially compromised barrier layers
- AnQlar may be used as a frontline defense against disease spread in close settings
- AnQlar may be used by vaccinated and unvaccinated individuals to prevent viral spread
- AnQlar shown to inhibit the ability of the virus to replicate at non-toxic concentrations
- May be a viral barrier against influenza and SARS-CoV-2 for 24 hours
- May prevent brain viral load due to flu and SARS-CoV-2
- Targeted delivery and viral barrier activity in the nasal mucosa where viruses start
MECHANISM OF ACTION
AnQlar and Quaternary Ammonium Chitosan (QAC) are highly related; Chitosan is a natural anti-microbial. Both are very positively charged mucoadhesive molecules that bind electrostatically to negatively charged coronaviruses.
AnQlar’s modified chemical structure makes the molecule more hydrophilic than QAC. AnQlar’s hydrophilic property allow it to self assemble into nanoparticles in water to improve viral barrier activity at the surface cell at pH levels acceptable for use in humans. AnQlar prevents viral entry into cells via the angiotensin-converting enzyme-2 (ACE-2) receptor.
OTC MEDICAL DEVICE
Epoladerm™
Diclofenac topical spray film
IND Enabling Trials Completed
DELIVERY PLATFORM
Topical spray film
POTENTIAL BENEFITS
- Improved drying, less messy, and better bioavailability
- Reliable and reproducible blood levels
- Improved patient compliance that could result in enhanced therapeutic outcomes
- Sustained pain control over 24 hours with one application
“Osteoarthritis is a painful condition that results in reduced physical function and quality of life and increased risk of all-cause mortality. A large, recent meta-analysis on pharmacologic treatments for knee and hip osteoarthritis indicated that topical diclofenac had the largest effect on pain and physical function with a better safety profile than oral diclofenac and might be the best treatment in terms of effectiveness and safety. These agents should be considered as a first-line pharmacological treatment for knee osteoarthritis.“
BRITISH MEDICAL JOURNAL
2021;375:N2321
MECHANISM OF ACTION
Topical Diclofenac Epolamine has an anti-inflammatory/antipyretic/analgesic action due to the inhibition of prostaglandin synthesis by inhibition of cyclooxygenase.
CONSUMER OTC
Drug Application Process for Direct to Nonprescription or direct-to-OTC Drugs
Under the drug application process, a sponsor of a nonprescription drug submits a New Drug Application (NDA)or an Abbreviated New Drug Application (ANDA) to FDA for approval. One important difference between a drug application for a prescription drug and a nonprescription drug is that consumer behavior studies are often needed to demonstrate that consumers can use the nonprescription drug product safely and effectively without the supervision of a healthcare provider. FDA encourages all potential drug sponsors to initiate contact with the Office of Nonprescription Drugs (NDA products) or the Office of Generic Drugs (ANDA products) as early as possible, so that drug sponsors can consider FDA’s product development recommendations.
